Topic: Vytorin

Summary Box: Sales of Merck cholesterol pill will still fall, despite lack of safety problemsVYTORIN STUDY: A safety monitoring board doing a planned interim analysis of a long study of Merck's Vytorin cholesterol pill decided there are no serious safety problems, so ...

Sales of Merck & Co.'s blockbuster cholesterol drug Vytorin likely will continue to fall amid rising competition from rival brands and generic versions in the same class of pills, an analyst predicted Friday. Bernstein Research analyst Tim Anderson gave his assessment after ...

NEW YORK (Reuters) - Merck & Co on Thursday said an independent data safety monitoring board has approved continuation of a big study meant to determine whether its blockbuster Vytorin cholesterol drug prevents heart attacks and stroke. Merck said a green light ...

There's no evidence Merck & Co.'s blockbuster cholesterol drug Vytorin causes cancer, federal regulators said Tuesday. They reviewed reams of data after a patient study last year raised suspicions of a link, weakening sales already hurt by questions about the drug's efficacy. ...

Mylan sued by Schering over plans to make generic version of cholesterol drug VytorinMylan Inc. said Tuesday it being sued by Schering Corp. and MSP Singapore over plans to make a generic version of the cholesterol drug Vytorin. Mylan asked for Food ...

Author: Stuart Miles If you are suffering from high cholesterol then there are a number of different types of medication that your doctor can prescribe you and they will have both their advantages and disadvantages. Some of them are designed to make ...

Niacin shrinks artery plaque; Merck's Zetia does not and may carry risks, new study findsA new study raises fresh concerns about Zetia and its cousin, Vytorin — drugs still taken by millions of Americans to lower cholesterol, despite questions raised last year ...

Merck, Schering-Plough paying $41.5 million to settle class-action lawsuit over VytorinMerck & Co. and Schering-Plough Corp. said Wednesday they will pay $41.5 million to settle lawsuits claiming the drugmakers, partners on two blockbuster cholesterol drugs, delayed unfavorable study results because they would ...

Merck, Schering to pay $5.4M to resolve probes by 35 states into cholesterol drug studiesDrugmakers Merck & Co. and Schering-Plough Corp. said Wednesday they will pay $5.4 million to settle a multistate investigation that the companies delayed the release of test results ...

Schering-Plough CEO Fred Hassan's compensation falls 34 percent in 2008Schering-Plough Corp. Chief Executive Fred Hassan's compensation slipped 34 percent in 2008, mainly due to a decline in stock-based awards as the company's share price fell, according to an Associated Press analysis of ...